Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
Clinical trial NCT04683198 · UNKNOWN
Trial details
- NCT number
- NCT04683198
- Sponsor
- Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-01
- Primary completion
- 2023-10-30
- Enrollment
- 69
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.